SKU
AZ-BPC157-10, AZ-BPC157-20
BPC-157
In Stock
From $70.00
You save (%)
Fulfillment Timing Based on Inventory and Account Status.
BPC-157
HPLC Certified
CAS #
137525-51-0
M.W.
1419.5
Formula
C62H98N16O22
- PURITY
- ≥99%
RUO
- (Research Use Only)
Specs:
- Amount: 10mg | Format: Lyophilized Powder | Container: 3mL Vial | Storage: 2-8°C | Type: Single Peptide | Research Alias: BPC-157 | Research Category: Peptide Signaling Research
BPC-157 Peptide | Gastric Pentadecapeptide BPC | Azoth
What Is the BPC-157 Peptide?
BPC-157 is a synthetic peptide derived from a naturally occurring protein found in human gastric juice. Short for Body Protection Compound-157, this gastric pentadecapeptide is composed of a sequence of 15 amino acids and has become one of the most widely studied compounds in laboratory research and regenerative science.
Researchers studying tissue repair, wound healing, and cellular regeneration have shown significant interest in this stable gastric pentadecapeptide bpc sequence due to its broad range of observed effects across various tissues in preclinical models. Animal models, particularly studies in treated rats, have documented effects on muscle, tendon, ligament, bone, and gastrointestinal tissues, making BPC-157 one of the most versatile peptides under active investigation today.
At Azoth, we offer pharmaceutical-grade BPC-157 peptide synthesized to the highest purity standards, intended exclusively for licensed researchers and laboratory professionals.
How Does BPC-157 Work? Several Mechanisms Explored
The gastric pentadecapeptide bpc 157 peptide does not appear to operate through a single receptor pathway. Instead, preclinical research suggests it acts as a pleiotropic regulator, modulating several mechanisms across interconnected biological systems relevant to tissue repair in in vitro and animal model contexts.
Vascular Signaling and New Blood Vessel Formation
One of the most documented findings in BPC-157 research is its role in angiogenesis, the process of new blood vessel formation. Studies in animal models suggest this peptide enhances the upregulation of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), sensitizing endothelial cells to circulating growth factors. This VEGFR2-Akt-eNOS signaling axis promotes blood vessel formation and endothelial cell proliferation, a mechanism with implications across cardiovascular, neurological, and musculoskeletal preclinical research. [1, 2]
Cellular Migration and Collagen Production
BPC-157 has demonstrated a dose-dependent effect on fibroblast proliferation and migration in both in vitro and in vivo models. Fibroblasts are the cells responsible for collagen deposition and the formation of extracellular matrix proteins including elastin and fibrin. By stimulating the FAK-paxillin pathway, the compound promotes cellular adhesion and movement, which are crucial steps observed in preclinical wound healing and tissue reconstruction models. [3, 4]
Nitric Oxide Homeostasis
This stable gastric pentadecapeptide exhibits a stabilizing effect on the nitric oxide (NO) system in animal models, supporting localized vasodilation and simultaneously protecting tissues from damage caused by both NO excess and deficiency. This dual regulatory function contributes to its overall cytoprotective profile as observed in preclinical studies. [5]
Growth Hormone Receptor Sensitization
In models using tendon fibroblasts, BPC-157 exposure was shown to upregulate Growth Hormone Receptor (GHR) expression. This sensitization potentiated the downstream JAK2-STAT signaling cascade, with particular relevance to cellular regeneration at myotendinous junctions and sites of connective tissue injury in preclinical models. [6]
Buy BPC-157 Peptide for These Research Applications
Tendon and Ligament Healing
Tendon injuries and ligament healing remain among the most challenging areas in musculoskeletal and connective tissue research. The limited vascular supply to tendons and ligaments slows the rate at which reparative cells can reach injury sites in animal models. Preclinical research has demonstrated that BPC-157 can accelerate healing in these tissues by promoting collateralization, fibroblast density, and collagen production at the repair site. Studies in animal models show this peptide enhances observed outcomes beyond what is recorded with bFGF, EGF, and VGF hormones in comparable models. [3, 7]
Gastrointestinal Research and the Gut Lining
The natural parent compound of BPC-157 originates in the gastric mucosa, and much of the early research focused on its ability to support the gut lining in preclinical models. In vitro and animal studies have explored its role in conditions affecting gastrointestinal integrity, including models of ulcerative colitis, leaky gut syndrome, and inflammatory bowel disease. Researchers have observed effects on mucosal barrier function and gastrointestinal motility, as well as the compound’s ability to reduce inflammation in gut tissue models. [8, 9]
Wound Healing and Tissue Repair
Across various tissues in animal models, BPC-157 has consistently demonstrated the ability to accelerate healing. Research in treated rats with skin burns, muscle tears, and surgical incisions has shown that this compound supports healing through the simultaneous recruitment of immune cells, promotion of angiogenesis, and acceleration of collagen production. The stability of this gastric pentadecapeptide in both acidic and enzymatic environments makes it a particularly interesting candidate for delivery pathway research. [1, 10]
Chronic Inflammation
A recurring theme across BPC-157 peptide studies is its observed ability to reduce inflammation and chronic inflammation at sites of tissue injury in animal models. Several mechanisms contribute to this preclinical profile, including NO modulation, reduction of reactive oxygen species, and attenuation of pro-inflammatory cytokine activity. Researchers have also investigated its potential to counteract the gastrointestinal side effects of NSAIDs and certain psychiatric medications, including protection against drug-induced damage in the stomach, brain, and heart in rat models. [5, 11]
Research Summary: What the Preclinical Science Shows
The body of preclinical research on the 15Y peptide is substantial. Researchers across gastroenterology, musculoskeletal biology, and investigational regenerative science have published findings from numerous animal model studies. Below is a summary of key preclinical research areas.
| Research Area | Model | Key Findings |
|---|---|---|
| Tendon and Ligament Healing | Rat tendon models | Enhanced collagen deposition, fibroblast migration, and tissue integrity at myotendinous junctions observed in preclinical models. |
| Angiogenesis | Rat ischemia models | Significant increase in collateral blood vessel formation in animal models. |
| Gut Lining and IBD | Rat colitis models | Improved mucosal barrier function observed in ulcerative colitis animal models. |
| Chronic Inflammation | Various animal tissues | Reduced oxidative markers and inflammatory signaling in animal models. |
| Drug Side Effect Mitigation | Rat models | Protection against NSAID-induced gastric damage and cardiac arrhythmia risk observed in rat models. |
| Bone and Muscle | Multiple animal models | Accelerated healing of bone fractures and muscle injuries in preclinical studies. |
While large-scale human clinical trials are not currently lacking, a Phase I clinical trial (NCT02637284) was registered on ClinicalTrials.gov to evaluate the safety and pharmacokinetics of BPC-157 in a small cohort formation. Additional case reports and observational studies continue to be reviewed. Larger, well-controlled clinical trials are necessary before any conclusions about efficacy can be drawn.
Why Researchers Choose Azoth for BPC-157 Peptide
Scientific rigor and product consistency are essential in laboratory research. Azoth provides BPC-157 manufactured to strict purity specifications, backed by third-party certificate of analysis documentation for each batch.
- Verified 98%+ purity via HPLC testing
- USA-manufactured under strict quality protocols
- Third-party tested for identity, purity, and stability
- Lyophilized powder format for maximum shelf stability
- Certificate of Analysis available for every batch
Whether your focus is wound healing mechanisms, cellular regeneration pathways, or vascular research in animal models, Azoth provides the compound quality your laboratory research demands.
Storage and Handling
BPC-157 is supplied in lyophilized (freeze-dried) powder form. Store at 2–8°C in a cool, dry environment away from direct light and moisture. After reconstitution with bacteriostatic water, keep refrigerated and use in accordance with your laboratory research protocol. Stability is maintained for up to 24 months when stored correctly in lyophilized form.
Legal Disclaimer
BPC-157 sold by Azoth is intended for laboratory and in vitro research use only. It is not approved by the Food and Drug Administration (FDA) for human consumption, medical use, diagnostic procedures, or veterinary use. This product has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease or medical condition. Bodily introduction of any kind into humans or animals is strictly prohibited by law. All purchasers must be licensed researchers or qualified laboratory professionals. By purchasing this product, you acknowledge that you are aware of the applicable regulations in your jurisdiction and that you will use this compound exclusively within a qualified research environment.
Referenced Citations
| Research Findings | Journal | Data | Source Link |
|---|---|---|---|
| 1. Huang T, et al. “Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro.” | Drug Des. Devel. Ther. | 2015; 9:2485-2499. | https://pubmed.ncbi.nlm.nih.gov/26028970/ |
| 2. Duzel A, et al. “Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights.” | World J. Gastroenterol. | 2017; 23(48): 8465-8488. | https://pubmed.ncbi.nlm.nih.gov/29358855/ |
| 3. Chang CH, et al. “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.” | J. Appl. Physiol. | 2011; 110(3): 774-780. | https://pubmed.ncbi.nlm.nih.gov/21030672/ |
| 4. Hu YL, et al. “FAK and paxillin dynamics at focal adhesions in the protrusions of migrating cells.” | Sci. Rep. | 2014; 4:6024. | https://pubmed.ncbi.nlm.nih.gov/25112647/ |
| 5. Drmic D, et al. “Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME.” | World J. Gastroenterol. | 2017; 23(29): 5304-5312. | https://pubmed.ncbi.nlm.nih.gov/28839428/ |
| 6. Krivic A, et al. “Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts.” | PMC | 2018. | https://pmc.ncbi.nlm.nih.gov/articles/PMC6271067/ |
| 7. Seiwert S, et al. “BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing.” | Curr. Pharm. Des. | 2018; 24(18):1972-1989. | https://pubmed.ncbi.nlm.nih.gov/29879881/ |
| 8. Sikiric P, et al. “Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing.” | Curr. Pharm. Des. | 2018; 24(18):1990-2001. | https://pubmed.ncbi.nlm.nih.gov/29879882/ |
| 9. Drmic D, et al. “Counteraction of perforated cecum lesions in rats: Effects of pentadecapeptide BPC 157, L-NAME and L-arginine.” | World J. Gastroenterol. | 2018; 24(48):5462-5476. | https://pubmed.ncbi.nlm.nih.gov/30574426/ |
| 10. Amic F, et al. “Bypassing major venous occlusion and duodenal lesions in rats, and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine.” | World J. Gastroenterol. | 2018; 24(47):5366-5378. | https://pubmed.ncbi.nlm.nih.gov/30510371/ |
| 11. Strinic D, et al. “BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats.” | Life Sci. | 2017; 186:66-79. | https://pubmed.ncbi.nlm.nih.gov/28882437/ |
| 12. ClinicalTrials.gov. “BPC-157 Phase I Trial in Healthy Volunteers (NCT02637284).” | https://clinicaltrials.gov/study/NCT02637284 | ||
| 13. PubMed. “Retrospective study: BPC-157 intraarticular injection for chronic knee pain.” | https://pubmed.ncbi.nlm.nih.gov/34324435/ |
Research use only
All AZOTH products are intended solely for laboratory research, analytical, and scientific use. Products are not for human consumption, human use, veterinary use, diagnostic use, therapeutic use, or administration of any kind.